Shares of PAREXEL International Co. (NASDAQ:PRXL) have received an average recommendation of “Hold” from the fifteen research firms that are currently covering the company. Three research analysts have rated the stock with a sell recommendation and twelve have given a hold recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $66.64.
Several brokerages have recently weighed in on PRXL. Zacks Investment Research raised shares of PAREXEL International from a “sell” rating to a “hold” rating in a research note on Wednesday, April 5th. Mizuho assumed coverage on shares of PAREXEL International in a report on Thursday, March 23rd. They set a “neutral” rating and a $86.00 target price on the stock. Credit Suisse Group AG cut shares of PAREXEL International from an “outperform” rating to a “neutral” rating in a report on Monday, February 6th. Deutsche Bank AG cut shares of PAREXEL International from a “hold” rating to a “sell” rating and dropped their target price for the stock from $66.00 to $53.00 in a report on Friday, February 3rd. Finally, Citigroup Inc cut shares of PAREXEL International from a “buy” rating to a “neutral” rating in a report on Friday, February 3rd.
In related news, SVP Sybrand Pretorius sold 8,050 shares of the business’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $65.12, for a total value of $524,216.00. Following the sale, the senior vice president now directly owns 9,950 shares in the company, valued at approximately $647,944. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gadi Saarony sold 2,325 shares of the business’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $64.54, for a total transaction of $150,055.50. Following the completion of the sale, the insider now owns 14,208 shares in the company, valued at $916,984.32. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRXL. Congress Asset Management Co. MA purchased a new stake in PAREXEL International during the fourth quarter valued at $50,054,000. Norges Bank purchased a new stake in PAREXEL International during the fourth quarter valued at $36,989,000. The Manufacturers Life Insurance Company purchased a new stake in PAREXEL International during the third quarter valued at $30,564,000. Morgan Stanley raised its stake in PAREXEL International by 85.5% in the third quarter. Morgan Stanley now owns 716,525 shares of the medical research company’s stock valued at $49,763,000 after buying an additional 330,254 shares during the period. Finally, BTIM Corp. purchased a new stake in PAREXEL International during the third quarter valued at $14,463,000. Hedge funds and other institutional investors own 91.44% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Analysts Set PAREXEL International Co. (PRXL) PT at $61.36” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/04/21/brokerages-set-parexel-international-co-prxl-pt-at-61-36-updated-updated.html.
PAREXEL International (NASDAQ:PRXL) traded up 0.455% during midday trading on Monday, hitting $62.865. 389,227 shares of the stock were exchanged. The firm has a market capitalization of $3.20 billion, a P/E ratio of 22.308 and a beta of 0.82. The firm’s 50-day moving average price is $62.93 and its 200 day moving average price is $64.15. PAREXEL International has a 1-year low of $51.16 and a 1-year high of $72.32.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
What are top analysts saying about PAREXEL International Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PAREXEL International Co. and related companies.